Andere talen Arvinas, Inc.

Aandelen

ARVN

US04335A1051

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
31,77 ^USD	-0,41%		-6,56%	-22,81%

24/04	Arvinas, Inc. Benoemt Randy Teel tot Chief Business Officer	CI
15/04	ARVINAS, INC. : HC Wainwright herhaalt koopadvies voor het aandeel	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer	24/04
Arvinas, Inc. Appoints Randy Teel as Chief Business Officer	24/04
Arvinas : 2024 Proxy Statement	17/04
Arvinas enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer	12/04
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug	12/04
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024	11/04
Novartis : accord de licence dans le cancer de la prostate	11/04
Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis	11/04
Novartis étend sa recherche contre le cancer de la prostate	11/04
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact	11/04
Novartis erweitert Pipeline mit Lizenzabkommen für Prostatakrebs-Kandidaten	11/04
Novartis licenses Arvinas' cancer drug for up to $1 billion	11/04
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer	11/04
Arvinas, Inc Enters into an Exclusive Strategic License Agreement with Novartis AG for the Development and Commercialization of Protac Androgen Receptor Protein Degrader Arv-766 for the Treatment of Prostate Cancer	11/04
Arvinas Appoints Noah Berkowitz as Chief Medical Officer	18/03
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer	18/03
Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee	18/03
Arvinas to Participate in Upcoming Investor Conferences	04/03
Arvinas' Q4 Net Loss Widens as Company Reports No Revenue	27/02
Arvinas, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Arvinas, Inc.

Aandelen

ARVN

US04335A1051

Andere talen

Filters